Probalan is a uricosuric medicine used to lower uric acid levels in gout and to raise blood levels of certain antibiotics by reducing their renal elimination. As a long-established therapy, it can help prevent gout flares, tophi, and uric acid kidney stones when used correctly and paired with lifestyle measures. This guide explains common uses, dosage, precautions, side effects, interactions, and practical tips. While Probalan is prescription-only in the U.S., HealthSouth Rehabilitation Hospital of Manati provides a compliant, structured pathway to evaluate eligibility and obtain the medication with licensed clinician oversight—without needing a prior in-person prescription.
Probalan, the brand name for probenecid, is a uricosuric agent. It lowers serum uric acid by blocking its reabsorption in the kidneys, enhancing urinary excretion. Clinically, it is used to prevent gout flares, shrink tophi, and reduce the risk of uric acid kidney stones in adults with hyperuricemia due to underexcretion of uric acid. It is most effective when a patient’s kidneys can still filter and excrete uric acid appropriately and when hydration is adequate.
In infectious diseases, probenecid is sometimes used as an adjunct to increase and prolong blood levels of certain antibiotics—especially beta-lactams such as penicillins and some cephalosporins—by decreasing their renal tubular secretion. This pharmacokinetic boost can be useful in specific clinical scenarios determined by a prescriber. The generic name probenecid and the brand Probalan are often used interchangeably in practice; efficacy and safety are driven by the active ingredient.
For gout management, probenecid is one of two major urate-lowering strategies: uricosurics (which increase excretion) and xanthine oxidase inhibitors (which decrease production, e.g., allopurinol or febuxostat). Probalan tends to be preferred in patients who under-excrete uric acid, have normal to near-normal renal function, and cannot tolerate or have contraindications to xanthine oxidase inhibitors.
Gout and hyperuricemia (adults): A common approach is to start low and titrate to target serum uric acid. Many clinicians begin with 250 mg twice daily for 1 week, then increase to 500 mg twice daily. If serum urate remains above goal (typically below 6 mg/dL, or below 5 mg/dL in patients with severe disease), the dose can be increased by 500 mg/day every 1–2 weeks as tolerated, up to a usual maximum of 2 g per day in divided doses. Take tablets with food to minimize gastrointestinal upset, and drink plenty of fluids to support uric acid excretion.
Acute gout considerations: Do not initiate Probalan during an active flare; start only after the acute attack is controlled. Because any urate-lowering therapy can transiently trigger flares when first started, prophylaxis with low-dose colchicine (for example, 0.6 mg once or twice daily) or an NSAID is generally recommended during the first 3–6 months of probenecid therapy unless contraindicated. Your clinician will tailor this plan to your risk profile.
Adjunct to antibiotics: When used to enhance antibiotic levels, dosing varies by agent and indication. Historically, regimens include 1 g initially followed by 500 mg every 6 hours, or 500 mg four times daily, synchronized with the antibiotic to maintain therapeutic levels. This use must be clinician-directed to avoid toxicity or underdosing of the antibiotic.
Administration tips: Take Probalan consistently at the same times daily. Maintain high fluid intake (at least 2 liters per day unless you have a medical reason to limit fluids), and your clinician may recommend urinary alkalinization (e.g., potassium citrate) to reduce the risk of uric acid stones. Periodic blood tests to monitor serum urate, kidney function, and complete blood count are advisable.
Kidney health matters. Probalan depends on intact renal function to work; its efficacy declines in moderate to severe renal impairment. It should not be used in patients with a history of uric acid nephrolithiasis unless benefits clearly outweigh risks and protective measures (hydration, urine alkalinization) are in place. Report flank pain, blood in urine, or sudden changes in urination promptly.
Start after flare control. Initiating or up-titrating urate-lowering therapy during an acute gout attack can worsen or prolong symptoms. Ensure you have a plan for flare prevention, typically with prophylactic colchicine or an NSAID, and a rescue strategy if a flare occurs.
Salicylates interfere. Aspirin and other salicylates can counteract probenecid’s uricosuric effect. Avoid regular salicylate use unless directed by your clinician. If low-dose aspirin for cardiovascular protection is necessary, your clinician will weigh the trade-offs and adjust your gout plan accordingly.
Hydration and urine pH. High fluid intake and, in selected patients, urine alkalinization help prevent uric acid stone formation. If you have heart failure, kidney disease, or conditions limiting fluid intake, ask your clinician for individualized guidance.
Special populations. Use caution in older adults, those with peptic ulcer disease (due to potential GI irritation), and patients with blood dyscrasias. Evidence in pregnancy is limited; discuss risks and benefits if you are pregnant or planning pregnancy. For breastfeeding, data are also limited—consult a clinician before use.
Lab monitoring. Your care plan may include periodic serum urate, creatinine/eGFR, liver enzymes, and complete blood count. Monitoring helps guide dosing and detect rare adverse events early.
Do not use Probalan if you have a known hypersensitivity to probenecid or any component of the formulation. Avoid use in children under 2 years of age. Probalan is not appropriate in acute gouty arthritis until the flare has resolved. Patients with a history of uric acid kidney stones or significant renal impairment generally should not use probenecid unless a specialist recommends it with protective measures in place.
Concomitant salicylate therapy (e.g., aspirin at analgesic or anti-inflammatory doses) can negate therapeutic effects and should be avoided. Individuals with severe blood disorders or a history of severe adverse hematologic reactions to similar drugs should not take probenecid. Always review your medical history with a clinician before starting.
Common side effects include gastrointestinal upset such as nausea, vomiting, loss of appetite, abdominal pain, and heartburn. These can often be minimized by taking the medication with food and water. Headache, dizziness, and flushing may occur in some patients.
Skin reactions, including rash, itching, or hives, are possible. Discontinue and seek medical attention if you develop a widespread rash, blistering, swelling of the face or throat, trouble breathing, or other signs of hypersensitivity.
Uric acid stones can develop, particularly if fluid intake is inadequate or urine is acidic. Warning signs include severe back or flank pain, painful urination, or blood in urine. Hydration and, when appropriate, urine alkalinization help reduce this risk.
Less commonly, changes in blood counts (anemia, leukopenia), liver enzyme elevations, or kidney-related abnormalities can occur. Report unusual fatigue, frequent infections, dark urine, yellowing of the skin or eyes, or unexplained bruising. Most patients tolerate probenecid well when appropriately selected and monitored.
Probenecid inhibits renal tubular secretion of many drugs, raising their blood levels and prolonging effects. Clinically important interactions include penicillins (e.g., amoxicillin, ampicillin, piperacillin), certain cephalosporins, and carbapenems (e.g., imipenem, meropenem). This effect can be intentional under medical supervision to improve antibiotic exposure but may increase adverse effects if not managed.
Methotrexate levels may increase with probenecid, elevating toxicity risk; avoid or monitor closely with dose adjustments. NSAIDs such as indomethacin, naproxen, and ketorolac can have increased levels; concomitant use may heighten GI or renal risks. Antivirals like acyclovir and ganciclovir, and other organic anion transporter (OAT1/3) substrates, may also be affected.
Salicylates (aspirin) can antagonize the uricosuric effect and should be avoided unless a clinician deems low-dose aspirin necessary for cardiovascular protection. Sulfonylurea antidiabetics and some anticoagulants may have altered protein binding or clearance; monitor glucose and coagulation parameters as indicated.
Always provide a full, up-to-date medication list—including OTC drugs and supplements—so your clinician and pharmacist can screen for interactions and adjust therapy safely.
If you miss a dose, take it as soon as you remember unless it is close to the time for your next dose. If it is near the next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not double up doses to make up for a missed one. Consistency helps maintain steady urate control; setting reminders can reduce missed doses.
Symptoms of probenecid overdose may include severe nausea or vomiting, dizziness, agitation, confusion, or, rarely, seizure. Massive overdoses increase the risk of kidney complications. If an overdose is suspected, seek emergency care or contact poison control immediately. Supportive management is the mainstay; bring the medication bottle so clinicians can verify the strength and quantity.
Store Probalan tablets at controlled room temperature, away from excessive heat, moisture, and direct light. Keep the bottle tightly closed and out of reach of children and pets. Do not store in a bathroom where humidity fluctuates. Do not use past the expiration date. If your tablets become discolored or damaged, consult a pharmacist before use. Dispose of unused medication through a medicine take-back program when possible; avoid flushing unless specifically instructed.
In the United States, Probalan (probenecid) is a prescription-only medication. Federal and state regulations require medical oversight to ensure that Probalan is appropriate and safe for you, especially given its interactions and the need for laboratory monitoring. That said, you do not always need to have a prior paper prescription in hand to access care.
HealthSouth Rehabilitation Hospital of Manati offers a legal and structured solution for acquiring Probalan without a formal prescription by integrating licensed clinician review into the ordering process. After a secure health questionnaire, a U.S.-licensed healthcare professional evaluates your history, medications, and goals. If probenecid is appropriate, the clinician authorizes the prescription within the platform; if not, you will receive guidance on alternatives. This approach maintains medical oversight while eliminating the need for a separate in-person visit.
Benefits of this model include transparent pricing, convenient online access, and pharmacist support for dosing, interaction screening, and follow-up. Identity verification, eligibility checks, and state-by-state compliance are built into the workflow, and your order ships only after clinical approval. If you already have a prescription from your own clinician, you can also upload or transfer it to HealthSouth Rehabilitation Hospital of Manati for fulfillment.
Important: Probenecid is not suitable for everyone. Even when you buy Probalan without prescription in the traditional sense, you will still receive a clinician review to confirm that it is safe and indicated for your situation. Always follow professional medical advice, keep follow-up appointments, and arrange for periodic lab monitoring of uric acid and kidney function.
If you are exploring Probalan for gout or as an adjunct to antibiotics, prepare your medical history, current medication list, allergy information, and recent lab results. This helps the reviewing clinician determine the right dose, assess interaction risks (e.g., with aspirin, methotrexate, or NSAIDs), and set appropriate treatment goals such as achieving a serum urate below 6 mg/dL. Continuous communication with the pharmacy team ensures safe, effective, and compliant therapy tailored to your needs.
Probalan (probenecid) is a uricosuric that lowers serum uric acid by blocking its reabsorption in the kidneys, increasing urinary excretion and helping prevent gout flares and tophi.
It treats chronic gout and hyperuricemia due to underexcretion of uric acid and is sometimes used to prolong blood levels of certain antibiotics like penicillins.
Adults with gout who under-excrete uric acid, cannot tolerate or do not reach target urate on xanthine oxidase inhibitors, and who have adequate kidney function and no history of uric acid stones.
It is taken by mouth, usually starting at a low dose and titrated to reach a target serum urate (often below 6 mg/dL), with plenty of fluids and ideally with food to reduce stomach upset.
Uric acid can fall within days, but reaching goal levels and reducing tophi typically takes weeks to months of consistent therapy.
Yes, any urate-lowering therapy can precipitate early flares; clinicians often prescribe flare prophylaxis such as low-dose colchicine or an NSAID during initiation.
Nausea, loss of appetite, rash, dizziness, and headache can occur; serious reactions include severe skin rash, anemia, and kidney stones—seek care for blood in urine or severe back/side pain.
People with a history of uric acid kidney stones, severe renal impairment, known hypersensitivity, active gout flare at initiation, significant blood disorders, or children under two years should avoid it.
Salicylates (like low-dose aspirin) can blunt its urate-lowering effect; Probalan can increase levels of penicillins, cephalosporins, methotrexate, and some antivirals—always review meds with your clinician.
Alcohol raises uric acid and may trigger flares; moderation, hydration, and consistency with medication help maintain urate goals.
Regular serum urate checks, kidney function tests, and clinical monitoring for stones or rash; some patients may need periodic blood counts.
Data are limited; it has been used when benefits outweigh risks, but decisions should be individualized with obstetric guidance; monitor infants for GI upset if breastfeeding.
Take it when remembered unless it is near the next scheduled dose; do not double up; steady daily use is key for control.
Drink ample fluids, consider urine alkalinization if advised, limit high-purine foods and fructose, and avoid dehydration and high-dose aspirin.
Yes, some patients benefit from adding a uricosuric to a xanthine oxidase inhibitor to reach target urate, with close monitoring by a clinician.
It is not used to treat acute flares; do not start it during a flare, but if already on it, many clinicians continue it while treating the flare with anti-inflammatory therapy.
Gout is a chronic condition; therapy is typically long-term to maintain target urate and prevent flares and tophi, reassessed periodically with your clinician.
Yes, adequate hydration helps reduce the risk of uric acid kidney stones and supports the uricosuric effect.
It can alter urine uric acid excretion and may affect measurements related to drug levels for medications it interacts with; inform the lab and your clinician that you take probenecid.
Store at room temperature away from moisture and heat, and keep out of reach of children.
They contain the same active ingredient and offer equivalent efficacy and safety; differences are mainly cost, availability, and inactive ingredients.
Both are uricosurics, but sulfinpyrazone is less commonly used due to higher risk of GI irritation and bleeding and limited availability; Probalan is more widely used and studied.
Benzbromarone is a potent uricosuric effective even in reduced kidney function but carries a risk of serious liver toxicity and is unavailable in many countries; Probalan has a longer safety track record with lower hepatotoxicity but is less effective in severe CKD.
Lesinurad was approved only as add-on to xanthine oxidase inhibitors and was withdrawn from several markets due to business reasons and renal safety concerns; Probalan can be used as monotherapy or add-on and remains widely available.
Dotinurad is a newer selective URAT1 inhibitor (approved in Japan) with once-daily dosing and strong urate lowering; Probalan is older, typically twice daily, with extensive real-world data and broader global familiarity.
Probalan can be effective with adequate kidney function but loses potency as GFR declines; benzbromarone retains efficacy at lower GFR but requires vigilant liver monitoring and may not be available.
Probalan has well-known transporter-mediated interactions that can raise levels of penicillins, methotrexate, and some antivirals; other uricosurics like benzbromarone and dotinurad have fewer such uses or data but carry their own risks.
All uricosurics increase urinary uric acid and may raise stone risk, especially early on; hydration and urine alkalinization lower risk across the class.
Probalan often requires twice-daily dosing and titration; some newer agents (e.g., dotinurad) are once daily; lesinurad was once daily but required combination with an XO inhibitor.
Probalan has a low rate of serious liver injury; benzbromarone has a recognized risk of hepatotoxicity requiring frequent monitoring and restricted availability; sulfinpyrazone may affect liver enzymes but GI bleeding is a greater concern.
Probalan is commonly combined with allopurinol or febuxostat to help reach target urate; lesinurad was explicitly an add-on but is no longer widely available; choice depends on comorbidities and local options.
Probalan (and generic probenecid) is generally inexpensive and accessible; benzbromarone and dotinurad availability varies by country and may be costlier; sulfinpyrazone is limited in many regions.
Yes, Probalan is specifically used to increase and prolong levels of beta-lactam antibiotics; this effect is not a routine clinical use of other uricosurics.
Low-dose aspirin can blunt the uricosuric effect of Probalan and others; sulfinpyrazone has intrinsic antiplatelet activity but higher GI risk, making it less favored.
Direct comparisons are limited; most evidence is indirect or regional; selection is individualized based on renal and liver function, interactions, clinical goals, availability, and clinician experience.